# Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

> **NCT01301391** · PHASE2 · TERMINATED · sponsor: **Tiziana Life Sciences LTD** · enrollment: 30 (actual)

## Conditions studied

- Malignant Thymoma

## Interventions

- **DRUG:** Milciclib Maleate

## Key facts

- **NCT ID:** NCT01301391
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-02
- **Primary completion:** 2017-05-31
- **Final completion:** 2018-12-17
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** For the last patient still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301391, "Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01301391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*